Skip to main content

Anti-Contactin-Associated Protein-2 (CASPR2), Serum

CPT 86255

Test Details

Methodology

Immunofluorescence (IFA)

Result Turnaround Time

3 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

Anti-Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies. Patients with CASPR2 autoantibodies are very often elderly males. CASPR2 antibody-positive patients often have neuromyotonia or Morvan's syndrome, and some have forms of limbic encephalitis as well as neuropathic pain syndromes. All typically respond to immunotherapy.

This test works as an aid in the diagnosis of CASPR2 antibody disorders. This test is also useful in managing antibody-positive (CAPR2) individuals following immunotherapy and/or plasmapheresis.

This indirect fluorescent antibody assay utilizes CASPR2 transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

Special Instructions

If reflex test is performed, additional charges/CPT code(s) may apply.

Limitations

Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established product or procedure.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen Requirements

Specimen

Serum

Volume

2 mL

Minimum Volume

1 mL

Container

Gel-barrier tube, red-top tube, serum gel tube, serum transfer tube

Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

Storage Instructions

Room temperature

Causes for Rejection

CSF or plasma; contaminated, hemolyzed or severely lipemic specimens

References

Boyko M, Au KLK, Casault C, de Robles P, Pfeffer G. Systematic review of the clinical spectrum of CASPR2 antibody syndrome. J Neurol. 2020 Apr:267(4):1137-1146.31912210
Michael S, Waters P, Irani SR. Stop testing for auto-antibodies to the VGKC-complex: only request LGI1 and CASPR2. Pract Neurol. 2020 Oct;20(5):377-384.32595134
van Sonderen A, Petit-Pedrol M, Dalmu J, Titulaer MJ. The value of LGI1, CASPR2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017 May;13(5):290-301.28418022
Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 2019 Oct;40(10):2017-2030.31161339

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
505430 Anti-CASPR2, Serum 90820-2 505431 CASPR2 Antibody,Cell-based IFA 82979-6
Order Code505430
Order Code NameAnti-CASPR2, Serum
Order Loinc90820-2
Result Code505431
Result Code NameCASPR2 Antibody,Cell-based IFA
UofM
Result LOINC82979-6
Reflex Table for CASPR2 Antibody,Cell-based IFA
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 505432 Anti-CASPR2 Antibody Titer 505432 Anti-CASPR2 Antibody Titer 95600-3
Reflex 1
Order Code505432
Order NameAnti-CASPR2 Antibody Titer
Result Code505432
Result NameAnti-CASPR2 Antibody Titer
UofM
Result LOINC95600-3